Cargando…
A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study
BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571244/ https://www.ncbi.nlm.nih.gov/pubmed/37828455 http://dx.doi.org/10.1186/s12903-023-03411-2 |
_version_ | 1785119944995766272 |
---|---|
author | Sun, Shoufu Xu, Xiaodong Zhang, Zhongxiao Zhang, Ying Wei, Wenjia Guo, Ke Jiang, Yunan N. |
author_facet | Sun, Shoufu Xu, Xiaodong Zhang, Zhongxiao Zhang, Ying Wei, Wenjia Guo, Ke Jiang, Yunan N. |
author_sort | Sun, Shoufu |
collection | PubMed |
description | BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present study aimed at exploring safety as well as short- and long-term efficacy of this new protocol clinically. MATERIALS AND METHODS: A total of 66 participants were enrolled in this randomized single-blind clinical trial, and randomly allocated to control group (only blood clots), test A group (autogenous bone, Bio-Oss with barrier membrane) and test B group (autogenous bone, Bio-Oss, CGF gel with CGF membrane). The postoperative outcomes including PoSSe scale, periodontal probing depth (PD), degree of gingival recession and computed tomography measurements were assessed at 3rd, 6th, 12th month. A p-value < 0.05 was considered statistically significant. RESULTS: In PoSSe scale, no significant difference was observed except a significant alleviation of early-stage pain perception in test B group (p < 0.05). Also, test B group exhibited better effect on periodontal healing and gingival recession reduction after 6 months (p < 0.05). Both two test groups showed more new bone formation than the control group (p < 0.05). It is noteworthy that the bone repair of test B group was significantly better than that of test A at 3rd and 6th month (p < 0.05), yet no difference was observed at 12th month (p > 0.05). CONCLUSION: Both two test groups could achieve stable long-term efficacy on bone defect repair. The use of CGF gel and CGF membrane could accelerate early-stage bone repair, alleviate short-term pain after surgery, reduce long-term probing depth and relieve economic cost for patients. This new bone repair protocol is worthy of promoting by clinicians. TRIAL REGISTRATION: This study was registered with the identification number ChiCTR2300068466 on 20/02/2023 at Chinese Clinical Trial Registry. Also, it was ethically approved from the institutional ethics committee at the Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (No:2023-010-01), and has been conducted in accordance to the guidelines of the declaration of Helsinki. Written informed consent was obtained from all participants in the study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-023-03411-2. |
format | Online Article Text |
id | pubmed-10571244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105712442023-10-14 A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study Sun, Shoufu Xu, Xiaodong Zhang, Zhongxiao Zhang, Ying Wei, Wenjia Guo, Ke Jiang, Yunan N. BMC Oral Health Research BACKGROUND: The extraction of impacted mandibular third molars might cause large bone defects in the distal area of second molars. A new strategy was innovatively employed here combining autologous bone, Bio-Oss, concentrated growth factors (CGF) gel and CGF membrane for bone repair, and the present study aimed at exploring safety as well as short- and long-term efficacy of this new protocol clinically. MATERIALS AND METHODS: A total of 66 participants were enrolled in this randomized single-blind clinical trial, and randomly allocated to control group (only blood clots), test A group (autogenous bone, Bio-Oss with barrier membrane) and test B group (autogenous bone, Bio-Oss, CGF gel with CGF membrane). The postoperative outcomes including PoSSe scale, periodontal probing depth (PD), degree of gingival recession and computed tomography measurements were assessed at 3rd, 6th, 12th month. A p-value < 0.05 was considered statistically significant. RESULTS: In PoSSe scale, no significant difference was observed except a significant alleviation of early-stage pain perception in test B group (p < 0.05). Also, test B group exhibited better effect on periodontal healing and gingival recession reduction after 6 months (p < 0.05). Both two test groups showed more new bone formation than the control group (p < 0.05). It is noteworthy that the bone repair of test B group was significantly better than that of test A at 3rd and 6th month (p < 0.05), yet no difference was observed at 12th month (p > 0.05). CONCLUSION: Both two test groups could achieve stable long-term efficacy on bone defect repair. The use of CGF gel and CGF membrane could accelerate early-stage bone repair, alleviate short-term pain after surgery, reduce long-term probing depth and relieve economic cost for patients. This new bone repair protocol is worthy of promoting by clinicians. TRIAL REGISTRATION: This study was registered with the identification number ChiCTR2300068466 on 20/02/2023 at Chinese Clinical Trial Registry. Also, it was ethically approved from the institutional ethics committee at the Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (No:2023-010-01), and has been conducted in accordance to the guidelines of the declaration of Helsinki. Written informed consent was obtained from all participants in the study. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12903-023-03411-2. BioMed Central 2023-10-12 /pmc/articles/PMC10571244/ /pubmed/37828455 http://dx.doi.org/10.1186/s12903-023-03411-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Sun, Shoufu Xu, Xiaodong Zhang, Zhongxiao Zhang, Ying Wei, Wenjia Guo, Ke Jiang, Yunan N. A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title | A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title_full | A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title_fullStr | A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title_full_unstemmed | A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title_short | A novel concentrated growth factor (CGF) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
title_sort | novel concentrated growth factor (cgf) and bio-oss based strategy for second molar protection after impacted mandibular third molar extraction: a randomized controlled clinical study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571244/ https://www.ncbi.nlm.nih.gov/pubmed/37828455 http://dx.doi.org/10.1186/s12903-023-03411-2 |
work_keys_str_mv | AT sunshoufu anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT xuxiaodong anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT zhangzhongxiao anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT zhangying anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT weiwenjia anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT guoke anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT jiangyunann anovelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT sunshoufu novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT xuxiaodong novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT zhangzhongxiao novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT zhangying novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT weiwenjia novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT guoke novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy AT jiangyunann novelconcentratedgrowthfactorcgfandbioossbasedstrategyforsecondmolarprotectionafterimpactedmandibularthirdmolarextractionarandomizedcontrolledclinicalstudy |